Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma

References

• Attal M, Harousseau J L, Stoppa A M, Sotto J J, Fuzibet J G, Rossi J F, et al. A prospective, randomized tr autologous BM transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97
   PubMed Web of Science ®Google Scholar
• Majolino I, Vignetti M, Meloni G, Vegna M L, Scime R, Tringali S, et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica 1999; 84: 844–852
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau J L, Facon T, Guilhot F, Doyen C, Fuzibet J G, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–2502
   PubMed Web of Science ®Google Scholar
• Segeren C M, Sonneveld P, van der Holt B, Vellenga E, Croockewit A J, Verhoef G E, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003; 101: 2144–2151
   PubMed Web of Science ®Google Scholar
• Vogel W, Kopp H G, Kanz L, Einsele H. Myeloma cell contamination of PB stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation. J Cancer Res Clin Oncol 2005; 131: 214–218
   PubMed Web of Science ®Google Scholar
• Pilarski L M, Belch A R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34+ hematopoietic progenitors. Clin Cancer Res 2002; 8: 3198–3204
   PubMed Web of Science ®Google Scholar
• Stewart A K, Vescio R, Schiller G, Ballester O, Noga S, Rugo H, et al. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771–3779
   PubMed Web of Science ®Google Scholar
• Badros A, Barlogie B, Morris C, Desikan R, Martin S R, Munshi N, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574–2579
   PubMed Web of Science ®Google Scholar
• Maloney D G, Molina A J, Sahebi F, Stockerl-Goldstein K E, Sandmaier B M, Bensinger W I, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447–3454
   PubMed Web of Science ®Google Scholar
• Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, et al. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant 2003; 32: 1145–1151
   PubMedGoogle Scholar
• Bethge W A, Hegenbart U, Stuart M J, Storer B E, Maris M B, Flowers M E, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood 2004; 103: 790–795
   PubMed Web of Science ®Google Scholar
• Bellucci R, Alyea E P, Weller E, Chillemi A, Hochberg E, Wu C J, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood 2002; 99: 4610–4617
   PubMed Web of Science ®Google Scholar
• Cavo M, Terragna C, Martinelli G, Ronconi S, Zamagni E, Tosi P, et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355–357
   PubMed Web of Science ®Google Scholar
• Bjorkstrand B B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–4718
   PubMed Web of Science ®Google Scholar
• Bensinger W I, Demirer T, Buckner C D, Appelbaum F R, Storb R, Lilleby K, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793
   PubMed Web of Science ®Google Scholar
• Majolino I, Corradini P, Scime R, Falda M, Bosi A, Tarella C, et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant 2003; 31: 767–773
   PubMed Web of Science ®Google Scholar
• Kroger N, Sayer H G, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919–3924
   PubMed Web of Science ®Google Scholar
• Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367–373
   PubMed Web of Science ®Google Scholar
• Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, et al. Chronic Leukaemia Working Party of the EBMT. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005; 105: 4532–4539
   PubMed Web of Science ®Google Scholar
• Durie B G, Salmon S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, reponse to treatment, and survival. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Weisdorf D, Martin P, Klingemann H G, Beatty P, Hows J, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828
   PubMed Web of Science ®Google Scholar
• Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, et al. High-dose sequential chemoradiotherapy in multiple myeloma: Residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995; 85: 1596–1602
   PubMed Web of Science ®Google Scholar
• Voena C, Ladetto M, Astolfi M, Provan D, Gribben J G, Boccadoro M, et al. A novel nested PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997; 11: 1793–1798
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Van Lint M T, Valbonesi M, Lercari G, Carlier P, Lamparelli T, et al. Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood 1996; 88: 353–357
   PubMed Web of Science ®Google Scholar
• Lamparelli T, Van Lint M T, Gualandi F, Raiola A M, Barbanti M, Sacchi N, et al. Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin. Bone Marrow Transplant 2000; 26: 1305–1311
   PubMed Web of Science ®Google Scholar
• di Grazia C, Raiola A M, Van Lint M T, Lamparelli T, Gualandi F, Berisso G, et al. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft. Haematologica 2001; 86: 646–651
   PubMed Web of Science ®Google Scholar
• Raiola A M, Van Lint M T, Lamparelli T, Gualandi F, Mordini N, Berisso G, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol 2000; 109: 716–721
   PubMed Web of Science ®Google Scholar
• Rondelli D, Barosi G, Bacigalupo A, Prchal J T, Popat U, Alessandrino E P, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105: 4115–4119
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Bertola A, Cavallo F, Falco P, Massaia M, et al. Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2. Leukemia 2004; 18: 133–138
   PubMed Web of Science ®Google Scholar
• Garban F, Attal M, Michallet M, Hulin C, Bourhis J H, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474–3480
   PubMed Web of Science ®Google Scholar
• Majolino I, Saglio G, Scime R, Serra A, Cavallaro A M, Fiandaca T, et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555–560
   PubMed Web of Science ®Google Scholar
• Luft T, Moos M, Goldschidt H, Ho A D, Gorner M. Dissociation of putative graft-versus-haematopoiesis and graft-versus-myeloma effects in patients with rapidly progressive multiple myeloma. Br J Haematol 2003; 123: 646–653
   PubMed Web of Science ®Google Scholar
• Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, et al. Molecular remission after myeloablative stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–1929
   PubMed Web of Science ®Google Scholar
• Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005; 29: 961–966
   PubMed Web of Science ®Google Scholar
• Moreau P, Jouet J P, Kuentz M, et al. Myeloablative allogeneic stem cell transplantation as part of first-line therapy for de novo multiple myeloma: long term follow-up of patients registered in the French Society of Stem Cell Transplantation database (SFGM_TC). 11th Congress of the Europea Hematology Association, Amsterdam 15 – 18 June 2006. Haematologica 2006; 19(suppl s1)194, (abs)
   Google Scholar
• Kroger N, Zabelina T, Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A. Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status. Exp Hematol 2006; 34: 770–775
   PubMed Web of Science ®Google Scholar
• Bruno B, Giaccone L, Rotta M, Anderson K, Boccadoro M. Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. Leukemia 2005; 19: 1729–1738
   PubMed Web of Science ®Google Scholar